MétaCan
Menu
Back to cohort
Record W4405374533 · doi:10.1016/j.iotech.2024.100886

2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)

2024· article· en· W4405374533 on OpenAlexaff
A. De Caluwé, Xavier Catteau, Zoë Denis, Marcela Carausu, Isabelle Desmoulins, Emanuela Romano, Vincent Remouchamps, A. Baten, P. Poortmans, Cédric van Marcke, F. Rothé, Michail Ignatiadis, Martine Piccart, Denis Larsimont, John Stagg, Christos Sotiriou, Roberto Salgado, Laurence Buisseret

Bibliographic record

VenueImmuno-Oncology Technology · 2024
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsUniversité de Montréal
FundersJapanese Respiratory SocietyJapan Agency for Medical Research and Development
KeywordsAdenosineAdjuvantBlockadeOncologyStage (stratigraphy)MedicineInternal medicineBreast cancerRandomized controlled trialReceptorBiologyCancer

Abstract

fetched live from OpenAlex

Background: Immunotherapy has transformed treatment for advanced non-small cell lung cancer (NSCLC).However, reliable biomarkers for treatment selection remain scarce.Gut microbiota (GM) has emerged as a potential biomarker, but its role in chemo-immunotherapy for NSCLC is unclear.Methods: The phase III trial (JCOG2007, NIPPON) compared pembrolizumab plus platinum doublet chemotherapy (PC) and nivolumab-ipilimumab plus platinum doublet chemotherapy (NIC) in treatment-naïve advanced NSCLC patients without driver gene alterations.As an ancillary biomarker study, 270 patients with baseline fecal samples were analyzed for GM composition out of 295 patients enrolled in JCOG2007.16S rDNA sequencing was performed for the subsequent GM diversity and differential abundance analysis.Results: The beta diversity analysis of the overall cohort (n¼270) revealed distinct microbial structures between responders and non-responders, categorized by overall survival (OS) at 12 or 18 months.Subsequent LEfSe analysis identified specific bacterial genera that differed between the groups, with Fusicatenibacter, Butyricicoccus, and Blautia being enriched in patients with longer OS.Regarding adverse events (AEs), lower microbial alpha diversity and the presence of certain taxa were linked to a higher risk of severe AEs ( grade 4).Additionally, favorable genera, including Fusicatenibacter and Butyricicoccus, were associated with a lower risk of severe AEs.Lastly, regimen-specific analysis showed that higher abundance of Fusicatenibacter and Butyricicoccus in the NIC arm were linked to better OS compared to the CP arm (Hazard Ratio (HR) for OS ¼ 0.56 and 0.52, respectively).Conversely, the higher abundance of Prevotellaceae NK3B31 was associated with higher mortality risk in the NIC arm (HR for OS ¼ 2.33).Conclusions: GM may serve as a biomarker for chemo-immunotherapy in advanced NSCLC.Differences in microbial diversity and specific bacterial genera were associated with prognosis and severe AEs, with potential regimen-specific effects.These findings support integrating GM profiling into clinical practice to optimize first-line treatment strategies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.344
Teacher spread0.329 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueImmuno-Oncology TechnologySame topicCancer Immunotherapy and BiomarkersFrench-language works237,207